In one paragraphArticle in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04315948 (Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2020 to 2023Enrolled1,552ConditionsCorona Virus InfectionArmsRemdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Hydroxychloroquine, Standard of care
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Astrid MarchalLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0003-0648-8126 Thibault KerdilesAP-HP, Département des Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, Lariboisière, Paris, France.ORCID 0009-0000-3194-4694 Adrian GervaisLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-1083-5787 Paul BastardLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-5926-8437 Lucy BizienLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-9163-9122 Guillaume LingasUniversité Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.ORCID 0000-0001-8566-6220 Clément R MassonnaudUniversité Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.ORCID 0000-0003-0292-9668 Maude Bouscambert-DuchampLaboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des Virus Respiratoires France Sud, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0003-2841-1808 Alexandre GaymardLaboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des Virus Respiratoires France Sud, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0002-8194-6126 Nathan Peiffer-SmadjaUniversité Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.ORCID 0000-0003-1166-1958 France MentreUniversité Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.
Laurent AbelLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.
Anne PuelLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0003-2603-0323 Florence AderDépartement des Maladies infectieuses et tropicales, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0002-4778-4338 Aurélie CobatLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (Inserm) U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-7209-6257 DisCoVeRy Study Group
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMonogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7MInborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7MSingle gene inborn errors of immunity underlying SARS-CoV-2-related multisystem inflammatory syndrome in children: a new approach to tackle a seemingly old puzzleR21AI160576 · NIAID · ROCKEFELLER UNIVERSITY · PI ZHANG, SHEN-YING · 2022 to 2023
$466kAgence Nationale de la Recherche ANR-10-IAHU-01Agency for Clinical Research and Biomedical InnovationANR AAILC 01057100ANR AAILC 824110ANR AAILC ANR-21-LIBA-0002ANR AI2D ANR-22-CE15-0046ANR GENVIR ANR-20-CE93-003ANR-RHU COVIFERON Program ANR-21-RHUS-08Austrian Group Medical TumorBattersea & Bowery Advisory GroupBelgian Health Care Knowledge CenterDomaine d'intérêt majeur One Health Île-de-France R20117HDEuropean Commission 101015736European Regional Development FundEuropean Union's Horizon 2020 research and innovation programmeFisher Center for Alzheimer's Research FoundationFondation du SouffleFonds Erasme-COVID-Université Libre de BruxellesFrench Foundation for Medical Research EA20170638020French Foundation for Medical Research EQU201903007798General Atlantic FoundationGrandir-Fonds de solidarité pour l'enfanceHoward Hughes Medical InstituteInstitut National de la Santé et de la Recherche MédicaleIntegrative Biology of Emerging Infectious Diseases Laboratory of Excellence ANR-10-LABX-62-IBEIDJPB FoundationMD-PhD program of the Imagine InstituteMeyer FoundationMinistry of HealthNCATS NIH HHSNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIAID NIH HHS R01 AI163029NIAID NIH HHS R21 AI160576NIH Clinical and Translational Science Award program UL1TR001866NIH HHS R01AI088364NIH HHS R01AI163029NIH HHS R21AI160576Programme Hospitalier de Recherche Clinique PHRC-20-0351Rockefeller UniversitySCOR Corporate Foundation for ScienceSquare FoundationStavros Niarchos Foundation Institute for Global Infectious Disease ResearchSt. Giles FoundationThe French Ministry of Higher Education, Research, and Innovation MESRI-COVID-19University of Paris Cité and Imagine Institute
6 · The paper itselfAbstract
Autoantibodies neutralizing type I interferon (AAN-I-IFNs) underlie life-threatening COVID-19. In hospitalized COVID-19 patients of the DisCoVeRy trial (NCT-04315948), AAN-I-IFNs were associated with higher nasopharyngeal viral load at inclusion (P = 1.4 × 10-3) and delayed viral clearance (P = .013). Blood AAN-I-IFNs, high viral load and delayed clearance were also independent risk factors for critical COVID-19.
Indexed as
Antibodies, NeutralizingAutoantibodiesCOVID-19Interferon Type INasopharynxViral LoadAgedFemaleHospitalizationHumansMaleMiddle AgedAntibodies, NeutralizingAutoantibodiesInterferon Type Ianti-type I interferon autoantibodiesSARS-CoV-2viral load
Identifiers
PMID42053985
PMCPMC13460755
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390